RCi215, RCFB59 C9

General

Cell Line

hPSCreg name PFIZi013-A
Cite as:
PFIZi013-A (RRID:CVCL_IJ00)
Alternative name(s)
RCi215, RCFB59 C9
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
CSSi012-A
Donor's gene variants:
TARDBP
Donor diseases:
Amyotrophic lateral sclerosis
HVRDi009-A
(29e SOD1 L144F, 29e)
Donor diseases:
obsolete_amyotrophic lateral sclerosis
UHi002-A
(HEL13.1, ALS50)
Donor diseases:
obsolete_amyotrophic lateral sclerosis
UHi003-A
(ALS75, HEL15.14)
Donor diseases:
obsolete_amyotrophic lateral sclerosis
UCLi004-A
(RCi173, RCFB60c6)
Donor's gene variants:
C9orf72, C9orf72
Donor diseases:
Amyotrophic lateral sclerosis
Frontotemporal dementia
UCLi004-B
(RCFB60c7, RCi177)
Donor's gene variants:
C9orf72, C9orf72
Donor diseases:
Amyotrophic lateral sclerosis
Frontotemporal dementia
UCLi004-C
(RCi172, RCFB60c2)
Donor's gene variants:
C9orf72, C9orf72
Donor diseases:
Amyotrophic lateral sclerosis
Frontotemporal dementia
SAPi002-A
(ALS I, ALS I–FUS-R514S/wt, FUS-R514S/wt)
Donor diseases:
amyotrophic lateral sclerosis
NIMHi008-A
(NphyiALS1)
Donor's gene variants:
LDB3
Donor diseases:
Amyotrophic Lateral Sclerosis
UCSCi001-A
(SII-1802)
Donor diseases:
Amyotrophic Lateral Sclerosis
SAPi003-A
(ALS II, FUS-R521C/wt, ALS II–FUS-R521C/wt)
Donor diseases:
Amyotrophic lateral sclerosis
SAPi004-A
(ALS III, TDP43-A382T/A382T, ALS III-TDP43-A382T/A382T)
Donor diseases:
Amyotrophic lateral sclerosis
CHDIi001-A
(#1c8, CHDI-90002149)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
ZZUi010-A
(ZZU-iPS-AD-APP-001)
Donor diseases:
obsolete_Alzheimer's disease
CHDIi003-A
(#3c1, CHDI-90002151)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi005-A
(#5c4, CHDI-90002153)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi010-A
(#10c2, CHDI-90002158)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi020-A
(#20c2, CHDI-90002168)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi022-A
(#22c1, CHDI-90002170)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi026-A
(#26c3, CHDI-90002174)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi029-A
(#29c4, CHDI-90002177)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi031-A
(#31c1, CHDI-90002179)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi033-A
(#104c2, CHDI-90002181)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi034-A
(#105c1, CHDI-90002182)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi041-A
(#116c2, CHDI-90002189)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi048-A
(#125c2, CHDI-90002196)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi049-A
(#127c2, CHDI-90002197)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi055-A
(#133c5, CHDI-90002203)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
STBCi004-B
(SFC832-03-06)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
STBCi004-C
(SFC832-03-07)
Donor's gene variants:
LRRK2
Donor diseases:
Parkinson disease
ZZUi014-A
(ZZU-iPS-SCA3-002)
Donor diseases:
Spinocerebellar ataxia type 3
STBCi143-A
(SFC122-03-01)
Donor diseases:
Alzheimer disease
WTSIi470-A
(HPSI0516i-jory_9)
Donor diseases:
Hereditary ataxia
WTSIi621-B
(HPSI0916i-vorn_2)
Donor diseases:
Hereditary ataxia
WTSIi638-B
(HPSI0916i-zipi_5)
Donor diseases:
Hereditary ataxia
WTSIi479-A
(HPSI0616i-beyk_6)
Donor diseases:
Spastic paraplegia
Last update 5th October 2022
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Pfizer Limited - Pfizer (PFIZ)
Distributors

External Databases

BioSamples SAMEA4343623
Cellosaurus CVCL_IJ00
Wikidata Q54947267

General Information

Projects
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: allowed
Commercial use: allowed

Donor Information

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Lou Gehrig disease
  • Charcot disease
  • ALS
Genetic variants
TARDBP (target)
1p36.2
NM_007375.3:c.1144G>A
NP_031401.1:p.Ala382Thr
p.A382T mutation in TARDBP

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA4343604

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Please provide the contact information Clinical Department at UCL IoN
Is there other documentation provided to the donor for consenting purposes? Yes
Confirm that consent was obtained by a qualified professional Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? No
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? The National Hospital for Neurology and Neurosurgery & Institute of Neurology Joint REC
Approval number 09/H0716/64
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? The National Hospital for Neurology and Neurosurgery & Institute of Neurology Joint REC
Approval number 09/H0716/64
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
Passage number reprogrammed 4

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SSEA-1
No
SSEA-4
Yes
TRA 1-60
Yes
SSEA-1
No
SSEA-4
Yes
TRA 1-60
Yes
POU5F1 (OCT-4)
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
CXCR4
Unknown
SOX17
Unknown
Gata6
Unknown
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
VIM
Unknown
DCN
Unknown
MIXL1
Unknown
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
PAX6
Yes
NeuroD1
Yes
HES5
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Certificate of Analysis

Is there a certificate of analysis available?
Yes
Passage: 26

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
No autosomal or sex chromosome aneuplodies were detected
Passage number: 26
Karyotyping method: BoBs

Other Genotyping (Cell Line)